MD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Pediatrix Medical Group Inc (MD) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company's financials show some positive growth in net income and EPS, the recent revenue decline, mixed analyst ratings, and lack of significant positive catalysts suggest a cautious approach. Technical indicators are neutral to slightly bullish, but the absence of strong trading signals and muted sentiment in options and insider trading data do not support an immediate buy decision.
The stock shows slightly bullish technical indicators with a positive MACD histogram, bullish moving averages (SMA_5 > SMA_20 > SMA_200), and a neutral RSI at 62.237. Key support and resistance levels are at S1: 21.469 and R1: 23.333, with the current pre-market price of 22.86 sitting near the pivot level of 22.401.
Analyst Jefferies raised the price target to $27, indicating potential upside. The healthcare services sector is seen as defensive and benefiting from AI/automation trends, with favorable reimbursement backdrops.
Revenue declined by -1.71% YoY in Q4 2025, and volumes were weaker than expected. Analysts from UBS and Deutsche Bank have lowered price targets, citing ACA headwinds and volume concerns. No significant insider or hedge fund activity, and no recent news to act as a catalyst.
In Q4 2025, revenue dropped to $493.77M (-1.71% YoY), while net income increased to $33.68M (+10.51% YoY). EPS rose to $0.4 (+11.11% YoY), and gross margin remained stable at 100%.
Analyst ratings are mixed. Jefferies maintains a Buy rating with a raised price target of $27, while UBS and Deutsche Bank have lowered their price targets to $22 and $19, respectively, with Neutral and Hold ratings. Truist is broadly bullish on the healthcare services sector but maintains a Hold rating on MD.
